Neoadjuvant serplulimab with chemotherapy enhances event-free survival in PD-L1-positive gastric cancer, making it a promising strategy for surgeons.

• Median event-free survival was longer with serplulimab (not reached) compared to placebo (42 months) for patients with PD-L1 CPS ≥10 (HR 0.65, p=0.0082).
• In the overall patient population, event-free survival was also improved (not reached vs. 35.9 months; HR 0.73, p=0.015).

Consider serplulimab for PD-L1-positive patients to potentially improve surgical outcomes while minimizing adverse events.

• Grade 3+ treatment-related adverse events were lower in the serplulimab group (47%) versus placebo (59%).